- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Acuson and ATL settle patent dispute
Acuson and Advanced Technology Laboratories last week settleda patent dispute between the ultrasound competitors relating tomultiplane transesophageal (TEE) technology and an ultrasoundfocusing technique. The settlement ends lawsuits that had beenfiled
Acuson and Advanced Technology Laboratories last week settleda patent dispute between the ultrasound competitors relating tomultiplane transesophageal (TEE) technology and an ultrasoundfocusing technique. The settlement ends lawsuits that had beenfiled last year in federal courts in Washington and California.
ATL had claimed that Acuson was infringing on its TEE patents,while Acuson charged ATL will violating its patent for an ultrasoniclens with reduced delay range. As part of the settlement, Acusonagreed to pay ATL an undisclosed sum in royalty payments on TEEprobes it sells. The companies entered a cross-licensing agreementfor several patents, including the Acuson focusing patent.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
